The SIRFLOX Study
The SIRFLOX study evaluated the efficacy and safety of adding SIR-Spheres® Y-90 resin microspheres to a current first-line systemic chemotherapy in patients with non-resectable colorectal liver metastases.
SIRFLOX is the first large, randomized, controlled, open-label, multicenter international study to examine the use of chemo-radiotherapy in the first-line treatment of colorectal liver metastases.
With 530 patients recruited, SIRFLOX is the largest randomized interventional radiology study ever conducted in oncology.
SIRFLOX Study Design
SIRFLOX evaluated the patient benefits of adding SIR-Spheres Y-90 resin microspheres to a current first-line systemic chemotherapy regimen comprising mFOLFOX6 (with or without bevacizumab).
SIRFLOX recruited chemotherapy-naïve patients with non-resectable liver metastases from primary colorectal cancer, with or without limited extra-hepatic disease.
The design of the SIRFLOX study has been published in BMC Cancer by Gibbs et al.